Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Jun 2019
Historique:
received: 14 05 2019
revised: 28 05 2019
accepted: 01 06 2019
entrez: 6 6 2019
pubmed: 6 6 2019
medline: 26 11 2019
Statut: epublish

Résumé

Various rodent models have been proposed for basic research; however, the pathogenesis of human nonalcoholic steatohepatitis (NASH) is difficult to closely mimic. Lipopolysaccharide (LPS) has been reported to play a pivotal role in fibrosis development during NASH progression via activation of toll-like receptor 4 (TLR4) signaling. This study aimed to clarify the impact of low-dose LPS challenge on NASH pathological progression and to establish a novel murine NASH model. C57BL/6J mice were fed a choline-deficient l-amino-acid-defined (CDAA) diet to induce NASH, and low-dose LPS (0.5 mg/kg) was intraperitoneally injected thrice a week. CDAA-fed mice showed hepatic CD14 overexpression, and low-dose LPS challenge enhanced TLR4/NF-κB signaling activation in the liver of CDAA-fed mice. LPS challenge potentiated CDAA-diet-mediated insulin resistance, hepatic steatosis with upregulated lipogenic genes, and F4/80-positive macrophage infiltration with increased proinflammatory cytokines. It is noteworthy that LPS administration extensively boosted pericellular fibrosis with the activation of hepatic stellate cells in CDAA-fed mice. Exogenous LPS administration exacerbated pericellular fibrosis in CDAA-mediated steatohepatitis in mice. These findings suggest a key role for LPS/TLR4 signaling in NASH progression, and the authors therefore propose this as a suitable model to mimic human NASH.

Identifiants

pubmed: 31163617
pii: ijms20112724
doi: 10.3390/ijms20112724
pmc: PMC6600174
pii:
doi:

Substances chimiques

Amino Acids 0
Biomarkers 0
Lipopolysaccharides 0
NF-kappa B 0
Toll-Like Receptors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
J Gastroenterol Hepatol. 2003 Nov;18(11):1272-82
pubmed: 14535984
Cancer Res. 1992 Sep 15;52(18):5042-5
pubmed: 1516060
Gastroenterology. 2005 Jul;129(1):113-21
pubmed: 16012941
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112
pubmed: 16447287
Gastroenterology. 2006 May;130(6):1886-900
pubmed: 16697751
J Hepatol. 2007 Oct;47(4):556-64
pubmed: 17459514
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
World J Gastroenterol. 2008 Nov 21;14(43):6655-61
pubmed: 19034968
Jpn J Cancer Res. 1990 Nov;81(11):1081-4
pubmed: 1979975
J Inflamm (Lond). 2010 Mar 30;7:15
pubmed: 20353583
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
J Hepatol. 2011 Aug;55(2):415-25
pubmed: 21184788
Am J Clin Nutr. 2012 Apr;95(4):892-900
pubmed: 22338037
Am J Physiol Gastrointest Liver Physiol. 2012 Jun 1;302(11):G1310-21
pubmed: 22442158
Cell Metab. 2012 Jul 3;16(1):44-54
pubmed: 22768838
Mol Med. 2012 Dec 06;18:1346-55
pubmed: 22952059
Hepatology. 2013 Jul;58(1):120-7
pubmed: 23401313
Hepatology. 2014 Jun;59(6):2188-95
pubmed: 24375711
World J Gastroenterol. 2014 Jul 14;20(26):8525-34
pubmed: 25024607
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
Gastroenterology. 2016 Jan;150(1):11-3
pubmed: 26602217
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Lipid Res. 2017 Jan;58(1):178-187
pubmed: 27811231
Dig Dis Sci. 2017 Feb;62(2):396-406
pubmed: 27913996
Hepatol Res. 2017 Nov;47(12):1317-1328
pubmed: 28029729
Immunobiology. 2017 Jun;222(6):786-796
pubmed: 28132721
Cell Mol Gastroenterol Hepatol. 2017 Jan 17;3(3):469-483
pubmed: 28462384
Nat Med. 2017 Jul;23(7):829-838
pubmed: 28604704
Am J Pathol. 2017 Aug;187(8):1800-1813
pubmed: 28711154
Oncotarget. 2018 Jun 19;9(47):28638-28651
pubmed: 29983886
Hepatology. 2019 Mar 29;:null
pubmed: 30924946
Carcinogenesis. 1994 Oct;15(10):2201-6
pubmed: 7955054

Auteurs

Keisuke Nakanishi (K)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. nakanishi@naramed-u.ac.jp.

Kosuke Kaji (K)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. kajik@naramed-u.ac.jp.

Mitsuteru Kitade (M)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. kitadem@naramed-u.ac.jp.

Takuya Kubo (T)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. taku@naramed-u.ac.jp.

Masanori Furukawa (M)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. furukawa@naramed-u.ac.jp.

Soichiro Saikawa (S)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. saikawa@naramed-u.ac.jp.

Naotaka Shimozato (N)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. shimozato@naramed-u.ac.jp.

Shinya Sato (S)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. shinyasato@naramed-u.ac.jp.

Kenichiro Seki (K)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. seki@naramed-u.ac.jp.

Hideto Kawaratani (H)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. kawara@naramed-u.ac.jp.

Kei Moriya (K)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. moriyak@naramed-u.ac.jp.

Tadashi Namisaki (T)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. tadashin@naramed-u.ac.jp.

Hitoshi Yoshiji (H)

Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan. yoshijih@naramed-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH